Le Lézard
Classified in: Health
Subjects: CSR, PSF

The SPOT Equips Spring Breakers with Life-Saving Tools Amid Rising Fentanyl Risks


FORT LAUDERDALE, Fla., March 27, 2025 /PRNewswire/ -- As thousands of spring breakers descend upon South Florida, The SPOT is once again taking to the beaches to help keep young people safe. With fentanyl-laced substances and drink spiking on the rise, The SPOT is distributing free naloxone (Narcan) and drink covers while educating visitors on overdose prevention and harm reduction strategies.

Last year, The SPOT's team distributed over 9,000 doses of naloxone to beachgoers, empowering thousands of young people to act as first responders in overdose situations. This year, the initiative aims to reach even more spring breakers by increasing its distribution goal to 10,000 doses, ensuring critical resources are in the right hands before a crisis occurs.

"Many spring breakers don't realize that substances they use could be laced with fentanyl," said Emelina Martinez, Safe Syringe Exchange Services Manager for The SPOT. "Our goal is to put even more naloxone in their hands this year because a single dose can mean the difference between life and death."

In addition to naloxone, The SPOT will provide free drink covers to help prevent drink tampering at parties and bars. The team will also offer harm reduction education, equipping young people with the knowledge they need to stay safe and make informed decisions.

While overdose deaths are declining, fentanyl-laced substances remain a serious threat. According to the Centers for Disease Control and Prevention, over 72,000 opioid-related overdose deaths occurred in the U.S. in 2023, with fentanyl as the primary driver. Access to harm reduction tools like naloxone remains more critical than ever.

The SPOT is Broward County's only approved Syringe Services Program, operating as a mobile harm reduction and medical unit under Care Resource's Behavioral Health Department. Beyond Spring Break, The SPOT provides essential harm reduction supplies and basic medical care, connecting individuals to specialized services offered by Care Resource.

Unlike other public health initiatives, The SPOT does not receive government funding for harm reduction services. The program relies on private donors and organizations, including Care Resource, United Way, Gilead Focus, The Fishman Family Foundation, and the late Dr. Peter Cinelli, to continue its life-saving work.

"Our ability to provide these critical resources depend on community support," said Dr. Thomas Smith, Director of Behavioral Health Services at Care Resource and The SPOT. "Every donation helps us distribute more naloxone and harm reduction supplies to those who need them most."

For more information about The SPOT, to request naloxone, or to report an overdose reversal, please visit thespotbroward.org, call 954-566-SPOT (7768), or email [email protected]. Weekly schedules are posted on Instagram (@thespotbroward) and Facebook (The SPOT Broward).

About The SPOT:
The SPOT is a mobile medical clinic and outreach program operated by Care Resource, providing no-cost harm reduction resources and medical services to communities in need. Through education, prevention, and support, The SPOT aims to make a positive impact on public health and safety.

SOURCE Care Resource


These press releases may also interest you

at 15:15
Sensydia, a clinical-stage non-invasive cardiac assessment company, announced today that University of Minnesota investigators presented positive clinical findings from a recent study evaluating the company's AI-powered, non-invasive Cardiac...

at 14:41
Millions of children are at risk following a devastating 7.7 magnitude earthquake that struck Myanmar on 28 March, compounding an already dire humanitarian situation....

at 14:32
Akeso Inc. (9926.HK) ("Akeso", "the Company") released its 2024 annual report, emphasizing the company's key achievements in drug research, clinical development, and commercialization. In 2024, Akeso achieved key success in antibody therapy research...

at 14:30
Eli Lilly and Company today announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA (siRNA) therapy designed to lower the production of lipoprotein(a) [Lp(a)], a genetically inherited risk factor for heart...

at 11:00
Medtronic plc , a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evoluttm transcatheter aortic valve replacement (TAVR) system delivers...

at 10:00
Today, Novo Nordisk presented new data from the retrospective, observational SCORE study that assessed treatment with semaglutide 2.4 mg and the risk of major adverse cardiovascular events (MACE) in adults with overweight or obesity and established...



News published on and distributed by: